bevacizumab,panitumumab
amgen,roche,takeda
['bevacizumab', 'panitumumab', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm', 'beva']
discussion of lba1 at #asco22 with expert chiara cremolini. #panitumumab + #mfolfox6 vs #bevacizumab + mfolfox6 as 1l in ras-wt #mcrc. results from the #paradigm trial, by dr. yoshino. abstract: lba1
#meded
Independent and international experts in GI oncology supporting medical oncologists to give the best possible care to patients. Part of https://t.co/Y8pV8OaxOB